The pandemic has only deepened the already heavily-weighted oncology focus of many portfolios, and it’s targeted oncology opportunities that are catching the eyes of buysiders in 2021. A combination of...

The fight against COVID-19 is far from finished, but victory is close enough to start considering how the tools created to tame SARS-CoV2 will reshape the post-war world. As with World War II and the...

Unprecedented industry collaboration topped the “Best of 2020” list for BioCentury’s editorial team for a year in which there was no question what topped the “Worst” list. On the latest edition of...

Incubated by Atlas Venture and led by former Ipsen CBO Ivana Magovčević-Liebisch, Vigil launched last week with $50 million in series A financing to advance two TREM2 agonists in-licensed from Amgen in rare microgliopathy indications. “We’ve...

Although VelosBio appeared to be heading down the path to an IPO, the oncology company has instead accepted a $2.8 billion takeout offer from Merck now that the biotech’s antibody-drug conjugate has shown signs of...